Clomifene citrate
Clomifene citrate Brand names, Clomifene citrate Analogs
- Chlomaphene
- Chloramifene
- Chloramiphene
- Cisclomiphene
- Clomid
- Clomid (TN)
- Clomifene citrate
- Clomifene citrate (JP14)
- Clomifeno
- Clomiphene
- Clomiphene B
- Clomiphene Citrate
- Clomiphene citrate (Z,E)
- Clomiphene dihydrogen citrate
- Clomivid
- Clomphid
- Clostilbegyt
- Dyneric
- Genozym
- Ikaclomin
- Milophene
- Omifin
- Racemic clomiphene citrate
- Serophene
- Serophene citrate
- Zuclomiphene citrate
Clomifene citrate Brand Names Mixture
- No information avaliable
Clomifene citrate Chemical_Formula
C26H28ClNO
Clomifene citrate RX_link
http://www.rxlist.com/cgi/generic/clomiph.htm
Clomifene citrate fda sheet
Clomifene citrate msds (material safety sheet)
Clomifene citrate Synthesis Reference
No information avaliable
Clomifene citrate Molecular Weight
405.959 g/mol
Clomifene citrate Melting Point
No information avaliable
Clomifene citrate H2O Solubility
Slightly soluble
Clomifene citrate State
Solid
Clomifene citrate LogP
7.496
Clomifene citrate Dosage Forms
Capsule; Liquid; Powder; Tablet; Tablet (effervescent)
Clomifene citrate Indication
Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome). In some countries, it is also registered for use in men.
Clomifene citrate Pharmacology
Clomifene (previously clomiphene) is an orally administered, non steroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). Clomifene can lead to multiple ovulation, and hence increasing the risk of twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer, and weight gain. Clomifene is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomifene initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomifene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.
Clomifene citrate Absorption
Based on early studies with 14 C-labeled clomifene, the drug was shown to be readily absorbed orally in humans.
Clomifene citrate side effects and Toxicity
The acute oral LD50 of clomifene is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known. Toxic effects accompanying acute overdosage of clomifene have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomifene therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain.
Clomifene citrate Patient Information
No information avaliable
Clomifene citrate Organisms Affected
Humans and other mammals
